What is Leerink Partnrs’ Forecast for AC Immune Q2 Earnings?

AC Immune SA (NASDAQ:ACIU) – Leerink Partnrs issued their Q2 2025 earnings estimates for AC Immune in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings of ($0.17) per share for the quarter. The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for AC Immune’s Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.85) EPS and FY2026 earnings at ($0.60) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of AC Immune in a research note on Thursday, April 3rd.

AC Immune Stock Performance

Shares of NASDAQ:ACIU opened at $1.48 on Wednesday. The company has a market cap of $148.61 million, a P/E ratio of -3.22 and a beta of 1.49. The business’s 50-day simple moving average is $2.14 and its 200 day simple moving average is $2.70. AC Immune has a one year low of $1.43 and a one year high of $4.98.

Institutional Trading of AC Immune

Several hedge funds have recently bought and sold shares of the company. Quinn Opportunity Partners LLC bought a new stake in shares of AC Immune during the fourth quarter valued at about $27,000. Two Sigma Advisers LP purchased a new stake in shares of AC Immune in the fourth quarter valued at $36,000. Boothbay Fund Management LLC acquired a new stake in AC Immune during the 4th quarter worth about $38,000. RPO LLC purchased a new stake in shares of AC Immune during the fourth quarter worth $51,000. Finally, Jane Street Group LLC bought a new position in shares of AC Immune during the 4th quarter valued at $66,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.